Faculty Opinions recommendation of Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Gastroenterology ◽

10.1053/j.gastro.2016.07.039 ◽

2016 ◽

Vol 151 (5) ◽

pp. 893-901.e1 ◽

Cited By ~ 38

Author(s):

Eric Lawitz ◽

Nancy Reau ◽

Federico Hinestrosa ◽

Mordechai Rabinovitz ◽

Eugene Schiff ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Faculty Opinions recommendation of Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726172820.793515335 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)00052-9 ◽

2016 ◽

Vol 16 (6) ◽

pp. 685-697 ◽

Cited By ~ 300

Author(s):

Michael Manns ◽

Didier Samuel ◽

Edward J Gane ◽

David Mutimer ◽

Geoff McCaughan ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61793-1 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1087-1097 ◽

Cited By ~ 202

Author(s):

Mark Sulkowski ◽

Christophe Hezode ◽

Jan Gerstoft ◽

John M Vierling ◽

Josep Mallolas ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Gastroenterology ◽

10.1053/j.gastro.2016.07.038 ◽

2016 ◽

Vol 151 (5) ◽

pp. 902-909 ◽

Cited By ~ 38

Author(s):

Edward J. Gane ◽

Kris V. Kowdley ◽

David Pound ◽

Catherine A.M. Stedman ◽

Mitchell Davis ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Genotype 2 ◽

Faculty Opinions recommendation of Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726606112.793521810 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Genotype 2 ◽

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.15412 ◽

2021 ◽

Author(s):

Fei Kong ◽

Xiaoyu Wen ◽

Xiaofeng Wen ◽

Xiaozhong Wang ◽

Guicheng Wu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Chronic Hepatitis C Virus ◽

Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30343-1 ◽

2019 ◽

Vol 4 (2) ◽

pp. 127-134 ◽

Cited By ~ 32

Author(s):

Lai Wei ◽

Seng Gee Lim ◽

Qing Xie ◽

Kính Nguyen Văn ◽

Teerha Piratvisuth ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Chronic Hepatitis C Virus ◽

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

Liver International ◽

10.1111/liv.14633 ◽

2020 ◽

Vol 40 (11) ◽

pp. 2685-2693

Author(s):

Yanhang Gao ◽

Fei Kong ◽

Guangming Li ◽

Cheng Li ◽

Sujun Zheng ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Chronic Hepatitis C Virus ◽